Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced a private placement equity financing expected to generate approximately $3.35 million in gross proceeds. Under the securities purchase agreement, Estrella will issue 2,333,334 shares of common stock at $1.50 per share. The funds will be used to support the completion of Phase I of the STARLIGHT-1 clinical trial, which evaluates the EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for treating relapsed/refractory B-cell non-Hodgkin's lymphoma. Estrella's CEO, Cheng Liu, expressed confidence in the potential of their ARTEMIS® T-cell therapy, stating that the financing will advance the clinical development of EB103. The closing of the private placement is subject to customary conditions, and the company will file a registration statement with the SEC for the resale of the securities.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。